drugset / Trial / NCT04107428
Somatostatin in Living Donor Liver Transplantation
Phase 4
Unknown
56 enrolled
King Faisal Specialist Hospital & Research Center
CEINGE - Biotecnologie Avanzate, Napoli, Italia · collabFederico II University of Naples, Department of Clinical Medicine and Surgery, Naples, Italy · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Aim of the study is to investigate the safety and the efficacy of somatostatin as liver inflow modulator in patients with end-stage liver disease (ESLD) and clinically significant portal hypertension (CSPH) undergoing Adult-to-Adult living donor liver transplantation (A2ALDLT).
Timeline
- Start
- 2019-12
- Primary completion
- 2020-08
- Completion
- 2022-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Somatostatin | Traditional medicine (herbal / TCM) | 250 ug | Intravenous |